OSS: Evaluation of an Oral Sodium Sulfate Solution for Patients With Prior Difficult or Incomplete Cleansing

Sponsor
Queen's University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06051955
Collaborator
Pendopharm (Other)
120
2
1
12
60
5

Study Details

Study Description

Brief Summary

This case series aims to evaluate the effectiveness and tolerability of Oral Sulfate Solution (OSS) in patients who had previously experienced poor colonoscopy preparation.

Condition or Disease Intervention/Treatment Phase
  • Other: oral sodium sulfate
N/A

Detailed Description

This study aims to evaluate the effectiveness of Oral Sodium Sulfate (OSS) in patients who have had poor colon preparation in the past. The study includes patients who had issues during their previous colonoscopy, such as needing extensive washing, inadequate preparation, a recommendation for shorter surveillance intervals, or adequate preparation for larger polyps but not smaller lesions.

Poor colon cleansing during a colonoscopy can lead to more prolonged procedures, lower polyp detection rates, and the need for repeat procedures with shorter surveillance intervals. OSS is a low-volume osmotic agent that causes diarrhea and colon cleansing by drawing water into the intestine. Health Canada and the FDA have approved it, and it is given in two 177ml bottles in a split dose. OSS is known for its good effect, ease of use, and tolerability, and it may be a better option than traditional cleansing agents.

All participants will receive OSS and instructions for use before their next surveillance colonoscopy. The study will use questionnaires and patient diaries to assess the effectiveness of OSS and patient compliance and tolerability.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
This study will enroll participants who have experienced difficult or incomplete bowel cleansing in the past. All participants will use oral sodium sulfate as their cleansing agent.This study will enroll participants who have experienced difficult or incomplete bowel cleansing in the past. All participants will use oral sodium sulfate as their cleansing agent.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Evaluation of an Oral Sodium Sulfate Solution for Patients With Prior Difficult or Incomplete Cleansing, a Progressive Case Series.
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Other: oral sodium sulfate

OSS is a colon cleansing agent administered in a split dose fashion, inducing diarrhea by drawing water into the intestine.

Other: oral sodium sulfate
All participants enrolled in this study will use Oral Sodium Sulfate as their bowel cleansing agent.

Outcome Measures

Primary Outcome Measures

  1. Effectiveness [1-2 days]

    The primary outcome is proportion of patients with an adequate preparation (Boston preparation scale 6 or greater, with no section less than 2).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients Age 18 to 80 inclusive

  2. Able to read and understand the English language

  3. History of poor bowel prep defined as:

  • Required extensive washing, as noted in the narrative of the endoscopist report.

  • Inadequate preparation

  • Endoscopist recommended shorter interval surveillance due to poor prep

  • adequate for polyps >5mm but not smaller lesions

Exclusion Criteria:
  1. Patients who have inflammatory bowel disease

  2. Patients with ileus or bowel obstruction

  3. Patients with history of colorectal resection

  4. Patients receiving combined upper and lower endoscopies

  5. Patients with ascites

  6. Patients with previously documented severe renal impairment

  7. Unable to provide consent

  8. Pregnant or lactating female (females of child-bearing potential will undergo urine pregnancy testing)

  9. Patients who have had a recent myocardial infarction(<6months)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hotel Dieu Hospital Kingston Ontario Canada K7L 5G2
2 Hotel Dieu Hospital Kingston Ontario Canada K7L5G2

Sponsors and Collaborators

  • Queen's University
  • Pendopharm

Investigators

  • Principal Investigator: Lawrence Hookey, Queen's University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Lawrence Charles Hookey, Professor, Queen's University
ClinicalTrials.gov Identifier:
NCT06051955
Other Study ID Numbers:
  • 6039506
First Posted:
Sep 25, 2023
Last Update Posted:
Sep 25, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Lawrence Charles Hookey, Professor, Queen's University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 25, 2023